

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Madsen et al

Serial No.: To be assigned

Group Art Unit: To be assigned

Filed: November 16, 2001

Examiner: To be assigned

For: Glucagon Antagonists/Inverse Agonists

#4A
G3

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

Before the above-captioned application is taken up for examination, entry of the following amendment is respectfully requested:

IN THE CLAIMS:

Please cancel claims 3 and 6-18 without prejudice.

REMARKS

Claims 1, 2, 4, 5 and 19-36 are now pending following entry of this amendment

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: November 16, 2001

Richard W. Bork
Richard W. Bork, Reg. No. 36,459
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123



23650

PATENT TRADEMARK OFFICE

23650